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Abstract
Vasovagal syncope, a contributing factor to elderly falls, is the transient loss of conscious-
ness caused by decreased cerebral perfusion. Vasovagal syncope is characterized by
hypotension, bradycardia, and reduced cerebral blood flow, resulting in fatigue, altered
coordination, and fainting. The purpose of this study is to develop an animal model which is
similar to human vasovagal syncope and establish an awake animal model of vasovagal
syncope. Male Sprague-Dawley rats were subjected to sinusoidal galvanic vestibular stim-
ulation (sGVS). Blood pressure, heart rate, and cerebral blood flow were monitored before,
during, and post-stimulation. sGVS resulted in hypotension, bradycardia, and decreased
cerebral blood flow. One cohort of animals was subjected to sGVS while freely moving.
sGVS in awake animals produced vasovagal syncope-like symptoms, including fatigue and
uncoordinated movements; two animals experienced spontaneous falling. Another cohort
of animals was preconditioned with isoflurane for several days before being subjected to
sGVS. Isoflurane preconditioning before sGVS did not prevent sGVS-induced hypotension
or bradycardia, yet isoflurane preconditioning attenuated sGVS-induced cerebral blood
flow reduction. The sGVS rat model mimics elements of human vasovagal syncope patho-
physiology (hypotension, bradycardia, and decreased cerebral perfusion), including behav-
ioral symptoms such as fatigue and altered balance. This study indicates that the sGVS rat
model is similar to human vasovagal syncope and that therapies directed at preventing
cerebral hypoperfusion may decrease syncopal episodes and reduce injuries from synco-
pal falls.
Introduction
Vasovagal syncope (VVS) is characterized by a transient, self-limited loss of consciousness:
loss of postural tone, collapse, and spontaneous recovery [1]. Between 20–50% of adults will
experience at least one syncopal episode during their lifetime, and VVS is most common in the
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elderly with up to 23% of individuals over 70 years old affected and a 30% chance of reoccur-
rence [2]. Each year over 400,000 new syncope patients are diagnosedwith VVS, of which
2–5% require emergency room visits, placing an annual burden of $2.4 billion on U.S. health-
care [3, 4].
The mechanism underlying VVS is not fully understood, yet the current thinking is
decreased venous return to the heart causes vigorous contraction of the myocardium against
inadequately filled atria, triggering the Bezold-Jarisch reflex resulting in paradoxical hypoten-
sion, bradycardia [1, 5], and consequent decreased cerebral perfusion, leading to a loss of con-
sciousness [5]. The head-up tilt test is valuable in diagnosing VVS and understanding its
mechanism. Head-up tilt tests on patients (mean age: 42.5 years) have shown that sympathetic
nerve activity and myocardial contractility are reduced preceding the onset of syncope, fol-
lowed by a lowering of blood pressure [6, 7].
In a series of compelling experiments, Cohen and colleagues proposed a rat model of VVS
using sinusoidal galvanic vestibular stimulation (sGVS) [8–10]. Their groups found that sGVS
could produce temporary hypotension and bradycardia. These studies imply that sGVS in rats
mimics human vasovagal responses through activation of the otolith system [9]. While Cohen
and colleagues have provided considerable research in understanding the role of sGVS on pre-
cipitating the vasovagal response, a critical aspect, and the final sequela, of VVS has not been
explored: cerebral perfusion.
Despite VVS pathophysiology including the reductions in blood pressure and heart rate,
VVS culminates in loss of conscious, typically leading to a fall [11]. Although the consensus is
that cerebral hypoperfusion ultimately causes the fainting episode, currently there is limited
research and understanding of the role cerebral blood flow (CBF) plays in VVS pathophysiol-
ogy. To date, few clinical studies have been published measuring CBF before and during syn-
cope. In one study by Grubb et al., thirty syncope patients were subjected to the head-up tilt
test. During syncope, the mean CBF was observed to be 46 ± 17% lower than Baseline values
[12]. A second study evaluated CBF changes in syncope patients with no bradycardia or hypo-
tension during the episode. In these patients, the mean CBF was still markedly reduced during
syncope (26 ± 13% lower than Baseline values) [13]. Sung et al. also investigated CBF changes
during syncope in patients and found that standing or head-up tilt test induced syncopal-
related lowering of the mean CBF by 32 ± 11.6% (standing) and 30 ± 16.7% (head-up tilt test)
[14]. These studies, as well as the VVS paradigm, consider cerebral hypoperfusion as the pri-
mary sequelae of VVS. Therefore, an animal model of VVS must show reduction in cerebral
blood flow during syncope. Additionally, VVS patients are plagued by spontaneous loss of con-
sciousness. Therefore, a second key to an animal model of VVS is that behavioral changes
mimicking VVS symptoms are experiencedby awake animals.
Herein we utilize the sGVS model in rats to examine its impact on CBF and, in awake ani-
mals, behavior changes caused by sGVS. Our first hypothesis is sGVS in rats results in
decreased blood pressure and heart rate (HR), followed by reduced CBF, mimicking vasovagal
response in humans. Our second hypothesis is sGVS in awake animals will induce VVS-like
symptoms, namely fatigue followed by spontaneous fainting and recovery. Our third hypothe-
sis is isoflurane preconditioning will induce cardio- and neuro-protectivemechanisms, thereby
attenuating the effects of sGVS on blood pressure, HR, and CBF.
Materials and Methods
All experiments were carried out in accordance to the methods and procedures approved by
the Loma Linda University IACUC and Research Protection Programs, and conducted in com-
pliance with theNIH Guidelines for the Use of Animals in Neuroscience Research. A protocol
sGVS-Induced CBF Depression and Fainting
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was in place for early termination of experiments if animals became severely ill (determined by
the Loma Linda University veterinary staff).
Adult male Sprague-Dawley rats (280–320 g) were obtained from Harlan Laboratories
(Harlan Laboratories, Indianapolis, IN, USA). Animals were housed in a humidity and temper-
ature controlled room on a 12 hour light-dark cycle, and given food and water ad libitum. Dur-
ing all surgical procedures and methods during which rats were anesthetized, the body
temperature was maintained at 37 ± 0.5°C using a heating pad controlled using a rectal probe.
Animals were continuously monitored during all surgical procedures and methods. Animals
were randomly assigned to the groups in each experiment. After surgical procedures, betadine
was applied to the wound(s), and buprenorphine was administered subcutaneously (0.01 mg/
kg). At the end of the experiment, rats were euthanized via decapitation after deeply anesthe-
tized with 5% isoflurane. No animals died before the experimental endpoints were achieved.
Sixty-six rats were used in this study. Four animals were used in a pre-experiment to deter-
mine the optimal stimulation parameters for lowering mean arterial pressure (MAP) and HR,
while depressing CBF. Experiment 1 investigated the effect of sGVS on CBF (groups: Sham
and sGVS, n = 10/group). Experiment 2 examined the effect of sGVS in awake, freely moving
rats (groups: Sham and sGVS, n = 6/group). Experiment 3 evaluated isoflurane precondition-
ing as a potential therapy to prevent sGVS sequelae (groups: Sham, sGVS, and sGVS + isoflur-
ane preconditioning, n = 10/group). Sham animals were normal rats which underwent all
surgeries and electrode placement, had the MAP, HR, and CBFmeasured, but without ever
undergoing sGVS stimulation. Additional methodological details are available in S1 File.
sGVS
sGVS was induced using a computer-controlled stimulator (Grass Technologies, West War-
wick, RI, USA) which generates sinusoidal currents and applied via electrodes [8–10]. After
laser Doppler probe placement, two Ag/AgCl needle electrodeswere inserted into the skin over
the mastoids. The computer-controlled stimulator generated sinusoidal currents binaurally (2–
4 mA, 0.025–0.5 Hz). Rats were kept under anesthesia for a total of 67 minutes: 30 minutes for
surgeries (femoral artery catheterization, laser Doppler probe placement, and electrode place-
ment), duringmeasurement of the baseline (for MAP, HR, and CBF, 4 minutes), during sGVS
stimulation (3 minutes), and for 30 minutes post-stimulation.
Pre-Experiment: Determine the Optimal Parameters for Inducing sGVS
In four rats, to determine the optimal stimulation parameters for inducingMAP and HR
reductions, various combinations of amplitude and frequencies were tested: 2 or 4 mA at
0.025–0.5 Hz. The optimal stimulation parameters were determined to be the frequency and
amplitude which induced the greatest, most reproducible drop in MAP and HR among each of
the four animals. CBF was monitored in each rat to identify any CBF changes during stimula-
tion using the various sets of stimulation parameters. These four animals were not used in any
other aspect of this study. Rats were deeply anesthetizedwith 5% isoflurane and then decapi-
tated after completing the experiment.
Experiment 1: Effect of sGVS on Cerebral Blood Flow
Twenty animals were randomly assigned to either the Sham or sGVS group (n = 10/group).
Sham animals were normal rats which underwent all surgeries (burr hole, femoral artery cathe-
terization) and electrode placement, had the MAP, HR, and CBFmeasured, but without ever
undergoing sGVS stimulation. These animals were anesthetized with isoflurane for the same
duration as animals subjected to sGVS and were monitored for MAP, HR, and CBF changes
sGVS-Induced CBF Depression and Fainting
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for the same duration as sGVS animals (4 minutes of “Baseline”, 3 minutes of “Stimulation”
without electrical stimulation, and 30 minutes “Post-Stimulation”). Sham animals were used as
the control group.
One day before sGVS, rats were anesthetized and a burr hole was drilled in the skull (center:
5 mm proximal to the coronal suture, 4 mm right lateral of the sagittal suture) using a micro-
drill. Then bone wax was applied and the skin sutured. Betadinewas applied to the wound and
buprenorphine was administered subcutaneously (0.01 mg/kg). The animal was allowed to
recover before being returned to its home cage.
On the day of sGVS, a PE50 catheter was inserted and advanced 10–15 mm into the femoral
artery of an anesthetized rat. The catheter was connected to a transducer for continuous mea-
surement of MAP and HR using a blood pressure analyzer (Digi-Med BPA 400a, Micro-Med,
INC., Louisville, KY, USA) and the DMSI-400 software (Micro-Med, INC., Louisville, KY,
USA). After femoral artery catheterization, the burr hole was reopened, exposing the brain tis-
sue. A laser Doppler probe (OxyFlo probe, MNP100XP, AdInstruments Inc., Colorado Springs,
CO, USA) was used for continuous measurement of CBF using a blood flowmonitor (INI191,
AdInstruments Inc., Colorado Springs, CO, USA) and PowerLab (PL3504, AdInstruments
Inc., Colorado Springs, CO, USA) with the LabChart software (LabChart Pro, AdInstruments
Inc., Colorado Springs, CO, USA).
sGVS was induced for three minutes with a 4 mA amplitude and 0.025 Hz frequency. MAP,
HR, and CBF were continuously monitored for four minutes before sGVS, during stimulation
(3 minutes), and for 30 minutes post-sGVS. Thirty minutes after stimulation, the laser Doppler
probe was removed and the rats were deeply anesthetized with 5% isoflurane and then
decapitated.
Experiment 2: Effect of sGVS on Awake, Freely Moving Animals
Twelve animals were used to examine the effects of sGVS on awake animals. Animals were ran-
domly assigned to either the Sham or sGVS group (n = 6/group). Sham animals had electrodes
placed, but received no stimulation. MAP, HR, and CBF were not monitored in any animal for
experiment 2. The only surgical procedure performedwas electrode placement.
Electrodeswere placed while the animal was under anesthesia. Total duration of isoflurane
exposure during electrode placement was not longer than 10 minutes (range: 6–10 minutes).
Animals were allowed to recover from the effects of isoflurane for a minimum of 50 minutes
(range: 50–70 minutes) in a cage identical to its home cage without bedding, food, and water.
After the animal fully recovered, sGVS was induced for 3 minutes. The animal’s behavior was
recorded for 5 minutes before stimulation, during stimulation (3 minutes) and for 60 minutes
post-stimulation. Immediately after recording stopped (60 minutes post-stimulation), animals
were deeply anesthetized and decapitated.
Experiment 3: Effect of Isoflurane Preconditioning on sGVS
Thirty animals were randomly assigned to either the Sham, sGVS, or isoflurane precondition-
ing followed by sGVS group (n = 10/group). Sham animals served as the control group and
underwent all procedures as described in Experiment 1. All animals receiving sGVS (sGVS
only group and isoflurane preconditioning followed by sGVS group) underwent all surgical
procedures as described in Experiment 1.
Ten animals were subjected to five days of isoflurane preconditioning. Daily, isoflurane
(2.5%) was administered to animals for 90 minutes. The isoflurane preconditioning regimen
was completed five days before subjecting rats to sGVS. Four days after completing the isoflur-
ane preconditioning regimen, rats underwent the surgical procedure for creating the burr hole
sGVS-Induced CBF Depression and Fainting
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(see Experiment 1 and S1 File for details). One day later (five days after completing the isoflur-
ane preconditioning regimen), rats were subjected to femoral artery catheterization, laser
Doppler probe placement, and sGVS as described in Experiment 1. MAP, HR, and CBF were
monitored before, during, and for 30 minutes post-stimulation as described in Experiment 1.
Animals were anesthetized before, during, and after stimulation. All animals were deeply anes-
thetized and decapitated 30 minutes after stimulation (immediately after recording was
completed).
Data Processing and Statistical Analysis
All raw data was processed and analyzed by a blinded investigator. The data was divided into
three sections: Baseline (minutes 0–4), Stimulation (minutes 3–7), and Post-Stimulation (min-
utes 7–37). Within each section the data was averaged and the standard deviation (SD) calcu-
lated. Upon processing, the Post-Stimulation data had very large SD due to the variation in the
return to baseline values, thus the Post-Stimulation sectionwas subdivided into 0–5 Min, 5–10
Min, 10–20 Min, and 20–30 Min Post-Stimulation. Since there was significant variation
between animals (within the same group) in the raw Baseline values for the physiological
parameters measured, the change from Baseline values were computed for each section/subsec-
tion. The data is presented as the mean (% change from Baseline) ± SD. In Experiment 2, the
behavioral changes for animals during and post-sGVS are anecdotally described since func-
tional tests specifically related to VVS symptoms were lacking. Finally, the data was processed
to determine the amount of time after beginning stimulation that was required to observe a
rapid, sustained drop in CBF (CBF drop delay). The local minimums for the data obtained dur-
ing stimulation were identified. Each local minimumwas examined for 1) being greater than 3
SD change from Baseline, and 2) sustained depression compared to Baseline (more than 15 sec-
onds). The delay in CBF drop was the amount of time after beginning stimulation that the min-
imum occurred.Data was analyzed using two-way ANOVA with Sidak’s post-hoc test
(GraphPad Prism 6, La Jolla, CA). p<0.05 was considered statistically significant; p<0.1 was
considered as a tendency.
Results
In the pre-experiment, four rats were used to determine the optimal stimulation parameters
required to induce reproducible vasovagal-like response: reduction in blood pressure and heart
rate. Each animal was subjected to sGVS using the following stimulation parameters: current
amplitude was either 2 or 4 mA, frequencies were 0.025, 0.05, 0.1, or 0.5 Hz. The optimal stim-
ulation parameters for inducing cardiovascular depression in rats was found to be a 4 mA cur-
rent at 0.025 Hz (Fig 1II). This set of stimulation parameters induced depression of MAP and
HR in each animal. Monitoring of the cerebral blood flow indicated that this set of stimulation
parameters was also capable for causing a reduction in cerebral blood flow, as shown by
decreased cerebral perfusion units measured using laser Doppler flow. Other sets of parameters
were observed to produce MAP and HR depression in some animals but not others. For exam-
ple, the representative plot (Fig 1) shows that the 4 mA at 0.05 Hz, 4 mA at 0.1 Hz and 4 mA at
0.5 Hz currents also inducedmarked decreases in MAP and HR (IV, VI, and VIII, respec-
tively). However, these sets of stimulation parameters did not cause reductions in MAP and
HR in some animals. Thus, these sets of stimulation parameters were unable to cause reproduc-
ible lowering of MAP and HR. Additionally, the 4 mA at 0.1 Hz and 4 mA at 0.5 Hz currents
did not have any consequent CBF reductions (VI and VIII, respectively) despite the marked
lowering of MAP and HR. Based on the preliminary experiment, a 4 mA current at a frequency
of 0.025 Hz was used in Experiments 1–3.
sGVS-Induced CBF Depression and Fainting
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No mortality was observed in this study. A total of seven animals were removed from the
study since no vasovagal-like response was observed (i.e. lack of a decrease in MAP or HR com-
bined by a lack of oscillatory response of MAP or HR): two from the sGVS group in Experi-
ment 1, two from the sGVS group in Experiment 3, and three from the sGVS + Isoflurane
group in Experiment 3. In total, data was collected and analyzed for 18 animals in Experiment
1 (n = 10 for Sham, n = 8 for sGVS), 12 animals in Experiment 2 (n = 6 for Sham, n = 6 for
sGVS), and 25 animals in Experiment 3 (n = 10 for Sham, n = 8 for sGVS only, and n = 7 for
sGVS + Isoflurane Preconditioning).
Experiment 1 –sGVS Causes Decreased Cerebral Blood Flow
sGVS in rats causes a delayed but significant drop in CBF (Fig 2). Compared to sham animals,
sGVS causes a decrease in HR (p<0.05) and CBF (p<0.05), and a tendency to decreasemean arte-
rial pressure (MAP) (p<0.1) (Fig 3). Upon halting sGVS, MAP rapidly returned to a level indistin-
guishable from that of Sham (p>0.1). However, HR remained depressed compared to that of Sham
for 10 minutes post-sGVS (p<0.05 for 0–5 and 5–10Min Post-Stimulation). CBF was significantly
lowered compared to that of Sham up to 30 minutes post-sGVS (p<0.05 for each time range).
A tendency to decrease over time was observed in Sham and sGVS rats for MAP (Sham:
p<0.05 for Baseline vs 10–20 and 20–30Min Post-Stimulation; sGVS: p<0.1 for Baseline vs 10–
20 and 20–30Min Post-Stimulation) and HR (Sham: p<0.05 for Baseline vs 10–20 and 20–30
Min Post-Stimulation; sGVS: p<0.05 for Baseline vs 0–5, 10–20, and 20–30Min Post-Stimula-
tion). No time-dependent changes in CBF were observed for Sham. Other than themarked reduc-
tion in CBF caused by sGVS, the CBF in rats subjected to sGVS was also unaffected over time.
Experiment 2 –sGVS in Awake Animals Mimics Vasovagal Syncope
Symptoms
Awake, freely moving animals were subjected to sGVS to evaluate the effect of sGVS on behav-
ior. Before beginning sGVS, all animals exhibited normal behavior (balance, movements,
Fig 1. Effects of Various Sets of Stimulation Parameters on HR, MAP, and CBF. A representative plot of the
stimulator current (mA), heart rate (BPM), mean arterial pressure (mmHg), and cerebral blood flow (perfusion
units) is shown. Baseline data was collected for 4 minutes before beginning stimulation (minutes 0–4). Five
minutes of recovery was allowed after each stimulation event. Stimulation occurred for 3 minutes using eight
different sets of stimulation parameters: 2 mA at 0.025 Hz (I), 4 mA at 0.025 Hz (II), 2 mA at 0.05 Hz (III), 4 mA at
0.05 Hz (IV), 2 mA at 0.1 Hz (V), 4 mA at 0.1 Hz (VI), 2 mA at 0.5 Hz (VII), and 4 mA at 0.5 Hz (VIII). Red lines
highlight the start and stop of each stimulation event. The greatest drop in CBF (13.9%) occurred for the 4 mA,
0.025 Hz current (II).
doi:10.1371/journal.pone.0163280.g001
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walking, body tone). Sham animals continued to have normal behavior throughout the dura-
tion of electrode implantation (1.5–2 hrs). At the onset of sGVS, rats’ behaviors began to
change (Fig 4). First, the breathing rate began to fluctuate (slow and deep or shallow).Within
30 seconds, animals exhibited fatigue-like behavior, such as labored breathing and reduced
responsiveness to external stimuli (sound and light). Between 0.5 and 2 minutes (and for the
remainder duration of stimulation), rats began to show signs of abnormal movement; use of
limbs was slower, head swaying and/or head rotation, body swaying and/or leaning towards
one side. During this time, when animals walked, it was unbalanced/uncoordinated. During
sGVS, 2 animals had spastic movements and 2 animals had fainting-like behavior. The latter
two rats fell on their side, then had 1–2 seconds of either no movement or one limb spasm,
then recovered spontaneously. After stopping stimulation, the animals subjected to sGVS
exhibited fatigue-like behavior for up to 45 minutes after sGVS. Animals subjected to sGVS
recovered normal behavior 28 ± 9.5 minutes post-stimulation (range: 15–45 minutes).
Experiment 3 –Isoflurane Preconditioning Reduces the Effect of sGVS
Cerebral Blood Flow Depression
Mean Arterial Pressure. Compared to sham animals, sGVS decreasedMAP in rats pre-
conditioned with isoflurane (sGVS + Isoflurane Preconditioning (PC)) (p<0.05) and tended to
decreaseMAP in unconditioned animals (p<0.1) (Fig 5A). During sGVS, no difference was
observed for MAP between unconditioned and isoflurane preconditioned rats. After stopping
sGVS, the MAP of animals subjected to sGVS only and those that were isoflurane precondi-
tioned returned to levels indistinguishable from that of Sham. MAP for Sham and sGVS only
animals tended to decrease over time (p<0.1 Baseline vs 20–30 Min Post-Stimulation), which
was not observedPost-sGVS in isoflurane preconditioned rats.
Heart Rate. Rats subjected to sGVS had reducedHR during stimulation compared to that
of Sham for unconditioned and isoflurane preconditioned rats (p<0.05 for Sham vs sGVS and
sGVS + Isoflurane PC) (Fig 5B). Isoflurane preconditioning did not attenuate the impact of
Fig 2. sGVS Causes CBF Reduction. Representative plot of CBF (bottom, blue plot) changes during sGVS (top,
red plot). Baseline CBF (~1780 perfusion units) was collected for 4 minutes before beginning sGVS (at minute 4).
Approximately 1 minute after starting sGVS a significant drop in CBF was observed, which was maintained
throughout stimulation. After sGVS, CBF recovers, but does not return to baseline values.
doi:10.1371/journal.pone.0163280.g002
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sGVS on HR. The HR of animals subjected to only sGVS remained depressed for up to 10 min-
utes post-sGVS whereas HR of sGVS animals preconditioned with isoflurane returned to val-
ues that were not statistically different from that of Sham immediately after stopping
stimulation (p<0.05 Sham vs sGVS at 0–5 and 5–10Min Post-Stimulation). Over time, the HR
in Sham animals and unconditioned animals subjected to sGVS decreased (Sham: p<0.05
Baseline vs 20–30 Min Post-Stimulation; sGVS: p<0.1 for Baseline vs 0–5 and 5–10 Min Post-
Stimulation, p<0.05 for Baseline vs 10–20 and 20–30 Min Post-Stimulation), whereas isoflur-
ane preconditioned sGVS rats’ HR did not have any tendency to decrease over time.
Cerebral Blood Flow. During stimulation, CBF is significantly reduced in animals sub-
jected to sGVS compared to that of sham animals (p<0.05 Sham vs sGVS), and this reduction
is sustained for up to 30 minutes post-stimulation (p<0.05 Sham vs sGVS for each time range
post-sGVS) (Fig 5C). CBF of isoflurane preconditioned animals was also statistically lower
Fig 3. MAP, HR, and CBF Changes Induced by sGVS. (A) MAP tends to decrease during sGVS (p<0.1). After
sGVS, MAP recovers. Prolonged anesthesia causes a steady MAP drop in all rats (Sham: p<0.05 for Baseline vs
10–20 and 20–30 Min Post-Stimulation, p<0.1 for 0–5 Min Post-Stimulation vs 20–30 Min Post-Stimulation; sGVS:
p<0.1 between Baseline and 20–30 Min Post-Stimulation). (B) HR is significantly reduced for sGVS rats compared
to Sham during sGVS (p<0.05), and for up to 10 Min Post-Stimulation (p<0.05). Prolonged anesthesia causes
steady decline of HR in all rats (Sham: p<0.05 for Baseline vs 10–20 and 20–30 Min Post-Stimulation, p<0.05 for
0–5 and 5–10 Min Post-Stimulation vs 10–20 and 20–30 Min Post-Stimulation; sGVS: p<0.05 for Baseline vs each
time range post-sGVS, p<0.05 for 0–5 and 5–10 Min Post-Stimulation vs 20–30 Min Post-Stimulation). (C) CBF is
significantly reduced during sGVS compared to Sham (p<0.05) and remains depressed for up to 30 minutes post-
sGVS (p<0.05). Prolonged anesthesia does not significantly lower CBF in either sham or sGVS rats. * p<0.05 for
Sham vs sGVS for the given time variable.
doi:10.1371/journal.pone.0163280.g003
Fig 4. Behavioral Changes during sGVS in Awake Rats. Representative images of the changes in
behavior observed during sGVS in awake rats. Sinusoidal galvanic vestibular stimulation in the awake
animal induces similar symptoms as that experienced by VVS patients. Awake animals during stimulation
exhibit signs of fatigue-like behavior (reduced responsiveness and lethargy), labored breathing, altered
coordination, and even faint-like behavior (i.e. falling). Representative images from fainting-like behavior in
two animals are shown (A, B) with pre-faint-like stance (i), stance during the faint-like behavior (ii), and
spontaneous recovery within 1–2 seconds after the onset of the faint-like behavior (iii). (C) Representative
images of altered coordination and head swaying.
doi:10.1371/journal.pone.0163280.g004
sGVS-Induced CBF Depression and Fainting
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than that of sham animals during stimulation (p<0.05 Sham vs sGVS + Isoflurane PC). In iso-
flurane preconditioned animals, the reduced CBF continued for up to 30 minutes after sGVS
(p<0.05 Sham vs sGVS + Isoflurane PC for 0–5, 5–10, 10–20, and 20–30 Min Post-Stimula-
tion). However, isoflurane preconditioned rats had a significantly attenuated CBF drop com-
pared to unconditioned rats both during stimulation (p<0.05 sGVS vs sGVS + Isoflurane PC)
and at each time range post-stimulation (p<0.05 sGVS vs sGVS + Isoflurane PC at 0–5, 5–10,
10–20, and 20–30 Min Post-Stimulation).
Discussion
Sinusoidal galvanic vestibular stimulation in rats provides an experimentalmimetic of human
vasovagal-like response [8–10]. Herein, sGVS induced cardiovascular and cerebrovascular
depression in rats, as well as resulting in VVS-like symptoms in awake animals. The reduction
in CBF during sGVS was partially attenuated with isoflurane preconditioning despite isoflur-
ane preconditioning having no effect on sGVS-induced lowering of MAP or HR.
The sGVS model has been previously shown to cause lower MAP and HR in rats through
activation of the vestibular neurons in the otolith organs [9, 15]. In the landmark experiments
by Cohen and colleagues, sGVS in rats was established as an experimentalmodel mimicking
human vasovagal response and VVS [8–10]. In that series of experiments, sGVS was found to
cause rapid lowering of MAP and HR at stimulus amplitudes of 2–4 mA and frequencies of
0.008–0.4 Hz [8, 9] with the most effective stimulation frequency being 0.025 Hz [10]. Herein,
our findings support the findings that the optimal stimulation parameters for inducing vasova-
gal-like responses in rats is a 4 mA current at 0.025 Hz. Additionally, we found that not only is
sGVS capable of producing the cardio-vascular depression that mimics human VVS, but sGVS
also results in marked reduction of CBF. While HR and MAPmay contribute to the onset of
VVS-induced fainting, VVS pathophysiology culminates in decreased cerebral perfusion (i.e.
results in loss of consciousness) [5, 16].
Fig 5. Effects of Isoflurane Preconditioning on MAP, HR, and CBF Changes During and Post-sGVS. (A)
MAP is significantly reduced by sGVS in unconditioned and isoflurane preconditioned rats subjected to sGVS
compared to Sham (p<0.1 Sham vs sGVS, p<0.05 Sham vs sGVS + Isoflurane PC). MAP recovers immediately
upon stopping sGVS, but prolonged anesthesia has a tendency to steadily decrease MAP (Sham: p<0.1
Baseline vs 20–30 Min Post-S-Stimulation; sGVS: p<0.1 Baseline vs 20–30 Min Post-Stimulation). (B) During
sGVS, HR is significantly lowered by sGVS in unconditioned and isoflurane preconditioned rats compared to
Sham (p<0.05 for Sham vs sGVS and sGVS + Isoflurane PC). HR in unconditioned animals remains decreased
for up to 10 minutes post-sGVS, while the HR of isoflurane preconditioned rats recovers after sGVS stops.
Prolonged anesthesia causes continued decreased in HR for sham and unconditioned sGVS animals (Sham:
p<0.1 between Baseline and 20–30 Min Post-Stimulation; sGVS: p<0.05 for Baseline vs 10–20 and 20–30 Min
Post-Stimulation). (C) CBF is reduced by sGVS in unconditioned and isoflurane preconditioned animals
compared to Sham (p<0.05 for Sham vs sGVS and sGVS + Isoflurane PC), yet isoflurane preconditioning
attenuates the CBF reduction caused by sGVS (p<0.05 sGVS vs sGVS + Isoflurane PC). The CBF reduction
caused by sGVS remains for up to 30 minutes post-stimulation (p<0.05 for Sham vs sGVS and sGVS
+ Isoflurane PC for each time frame Post-Stimulation). * p<0.05 for Sham vs sGVS for the given time variable, #
p<0.05 for Sham vs sGVS + Isoflurane PC, & p<0.05 for sGVS vs sGVS + Isoflurane PC.
doi:10.1371/journal.pone.0163280.g005
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Similarities between the sGVS Rodent Model and Vasovagal Syncope
in Patients
VVS Phase 1: Progressive EarlyHypotension. In VVS patients, there are four distinct
phases of vasovagal syncope: progressive early hypotension, terminal vasodilatation, the synco-
pal episode, and the postfaint phase. The first phase, termed “progressive early hypotension,”
occurs for patients, during head-up tilt test, who are destined to develop syncope [5]. This
phase is characterized by a slow but continuous lowering of blood pressure and cardiac output,
as well as an increase in HR [5]. This phase may last up to 5 minutes. In rats, 7 of 16 animals
subjected to sGVS showed a brief (less than 20 seconds) rise in HR, with only 3 of those 7 ani-
mals showing a slow decline in BP during that period. Four of the 7 animals which showed a
rise in HR immediately following the start of stimulation had rapid lowering of blood pressure.
Further studies need to be performed to determine if these observations in fact correlate with
human VVS by measuring cardiac output [5].
VVS Phase 2: Terminal Vasodilatation. The second phase of VVS, termed “terminal
vasodilatation,” occurs during the last 2 minutes before syncope [5]. The characteristics of this
phase include a rapid reduction in blood pressure and a slowing of HR, with the decrease in
HR occurring after the rapid drop in blood pressure [5]. While in humans the sequence of
physiological changes leading to syncopemay be induced by a number of factors [5, 17], sGVS
in rodents more closely mimics this phase (typically skipping the progressive early hypotension
phase). In the majority of animals, MAP rapidly decreases after stimulation is started [8–10],
followed by slow decline in HR. A few animals (4 of 16) had a sharp decline in HR immediately
following the blood pressure drop.
Also observed in humans during the second phase of VVS is a slow decline in CBF which
precedes a rapid drop immediately before the syncopal episode [5]. In 11 of 16 rats, CBF did
not significantly change from Baseline before the sharp drop occurred.Only 5 of 16 animals
experienced a slow gradual decline in CBF preceding a rapid drop. In these five animals, the
decline in CBF (before the drop-off)occurred for 21 ± 5.6 seconds, with one exception in
which the gradual decrease in CBF happened over 120 seconds before the rapid drop.
VVS Phase 3: Syncope. The third phase of VVS is the transient loss of consciousness. In
this phase, blood pressure and HR are at their minimum values and have experienced sharp
falls just prior to the faint. However, this phase is primarily characterized by the rapid drop in
CBF. In VVS patients, the rapid decrease in blood pressure and HR precedes the syncopal epi-
sode by 30–120 seconds, but can be variable [5, 18–23]. In the rat model of sGVS, a delay from
the start of stimulation (and thus MAP and HR reductions) until the rapid drop in CBF was
observed.Rats subjected to sGVS experienced a sharp reduction in CBF 51 ± 21.7 seconds after
starting stimulation.When rats were preconditioned with isoflurane before sGVS, the delay in
the CBF drop was 72 ± 36.4 seconds. If one assumes that the rapid drop in CBF in rats corre-
sponds to the syncopal episode (i.e. loss of consciousness), then the delay in this drop is similar
to the amount of time observed in human VVS [5, 18–23]. Interestingly, this delay in CBF
drop observed in the sGVS rat model mirrors the “pre-syncope” window reported in humans.
Therefore, this model may be utilized for examining therapies, administered during the pre-
syncopal event, which are aimed at preventing the loss of consciousness.
To date, there has been a limited number of studies in which CBF was monitored during
syncope. Grubb et al. performed two independent studies measuring the change in CBF in
humans with VVS. In the authors’ first study, the mean CBF during syncope in twenty VVS
patients dropped by 46 ± 17% [12]. The second study by Grubb et al. evaluated the changes in
CBF during syncope in five patients in which hypotension and bradycardia was absent. Despite
these patients not having reduced blood pressure or HR, they experienced a syncopal episode
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which correlated with a decrease in the mean CBF of 26 ± 13% during syncope [13]. Sung et al.
observed reductions of the mean CBF in syncope patients during standing or head-up tilt test
to be 32 ± 11.6% and 30 ± 16.7%, respectively [14]. In rats, sGVS induces changes in CBF of
22 ± 11.7% (S1 Fig). The minor differences in the percent CBF reduction during syncope
between the rat sGVS model and human VVS may be attributed to the use of anesthesia in rats
(i.e. isoflurane blocks some of the CBF depressive effects of sGVS).
Finally, sGVS in awake animals produces behavior similar to that observed in humans dur-
ing VVS. During sGVS, awake animals were fatigued, had variable breathing, had uncoordi-
nated movements, and had head swaying [19]. Two animals even had fainting-like behavior:
spontaneous fall followed by 1–2 seconds of either no movement or jerky movements of one
limb, then spontaneous recovery. Humans have been reported to experience a number of
behavioral changes preceding the syncopal episode, including light-headedness, fatigue,
blurred vision, sweating, shortness of breath, palpitations, and nausea [11, 19]. These symp-
toms are reported in the majority of VVS patients, with fatigue being the most common (in
92% of patients) [11].
VVS Phase 4: Postfaint Phase. The final phase of VVS is the postfaint phase which is
characterized by recovery from the loss of consciousness. During this phase, blood pressure
and HR recover immediately in the majority of VVS patients, however some patients remain
hypotensive for up to 5 minutes [5]. In the sGVS rat model, MAP tends to return to levels
indistinguishable from sham animals. However, due to the hypotensive effects of isoflurane,
the MAP of sham animals begins to reduce Post-Stimulation. Yet the HR in sGVS rats remains
depressed for up to 10 minutes after stimulation is stopped.
Another postfaint observation, is that most VVS patients (up to 75%) experience post-syn-
cope behavioral changes, such as fatigue and lethargy, light-headedness, disorientation, nausea,
confusion, palpitations, and altered mental status [11, 19]. Although the exact cause of these
symptoms after VVS is unknown, the CBF in the rodent model of sGVS suggests that it may be
a prolonged depression of CBF. Despite MAP and HR recovering within 15 minutes after stim-
ulation in the rat model, CBF was reduced for up to 30 minutes after sGVS. This observation
may provide a physiological explanation for the postfaint symptoms observed in the awake rat
model (such as extreme fatigue) as well as the postfaint symptoms reported by VVS patients
[11, 19].
Limitations and Future Studies
To date, there still remains some aspects of VVS which need to be investigated in the sGVS rat
model. First, the mechanism of sGVS is still unclear. VVS in humans is related to vagal activa-
tion and sympathetic inhibition. Since the mechanism of sGVS is not known, it cannot yet be
labeled as a truemodel of VVS. Second, the mechanism of human VVS is characterized by
decreased cardiac output (lowered HR and/or stroke volume) resulting in hypotension, culmi-
nating in cerebral hypoperfusion [16]. The current understanding of the sGVS rat model does
not focus on cardiac output, but rather HR. Future studies should investigate cardiac output
during sGVS in rats. Third, the decreased blood pressure is within the range of cerebral autore-
gulation (50–150 mmHg), thus healthy humans are unlikely to experience reduced CBF. How-
ever, studies on the blood pressure and CBF changes in VVS patients have also found that
syncope can be induced despite the reduced blood pressure being within the cerebral autoregu-
lation range [7, 12, 14]. These reports are also supported by Grubb et al. and Sung et al. in stud-
ies which identified significant changes in CBF during syncope in patients with reduced blood
pressure that is within the cerebral autoregulation range [12, 14]. Furthermore, in syncope
patients, CBF lowering and syncope can occur even in the absence of hypotension and
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bradycardia [13]. Thus syncopemay rely less on blood pressures outside of the cerebral autore-
gulation range than previously thought. However, this phenomenon, as well as the effects of
sGVS on CBF need to be examined in greater detail to understand the cause of VVS despite
blood pressure being within the cerebral autoregulatory range. Fourth, the mean drop in blood
pressure induced by sGVS in rats is 8% which is less than observed in syncopal patients sub-
jected to head-up tilt testing (approximately 20–30% drop in blood pressure) [5, 12]. The
mechanism causing the CBF reduction in rats with only an 8% drop in blood pressure remains
to be investigated, but may in part be due to the animals being anesthetized, thereby having a
lower baselineMAP (compared to the MAP in awake rats), whereas VVS patients are fully
awake when syncope occurs. Fifth, the results of Experiment 2 (observing sGVS in freely mov-
ing rats) are qualitative. Currently no behavioral tests are available for quantifying the altered
behavior of rats during sGVS. In future studies we will develop a behavioral test(s) for identify-
ing behavioral changes in rodents during sGVS.
Conclusion
Herein, we advance the understanding of the sGVS rat model and its use as a pre-clinical
mimetic of VVS, as well as investigate a therapy for vasovagal syncope. To our knowledge, we
are the first to show that sGVS causes a CBF decrease, in addition to MAP and HR, with a
rapid decrease in MAP and HR preceding CBF reduction. After stimulation, whileMAP and
HR recover, CBF remains depressed for up to 30 minutes post-sGVS.We are also the first to
show that sGVS in awake rats produces VVS-like symptoms, including fatigue and fainting-
like behavior. Finally, we are the first to begin investigating therapies for VVS using the sGVS
rat model with the focus on attenuating cerebral hypoperfusion.We identified that isoflurane
preconditioning reduces CBF depression caused by sGVS, which may point to potential thera-
pies that can decrease syncopal episodes. The current study not only provides the basis for
using the sGVS rat model to examine the vasovagal response and develop novel therapies for
VVS, but also further establishes the sGVS rodent model as a close experimentalmimetic of
VVS in humans, in not only cardio- and cerebro-vascular effects, but also in behavioral
changes.
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